• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $GRPH

    Graphite Bio Inc.

    Subscribe to $GRPH
    $GRPH
    Medicinal Chemicals and Botanical Products
    Health Care

    Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: graphitebio.com

    Peers

    $CABA
    $GBIO
    $GOSS
    $GRTS
    $INMB
    $PASG
    $PRVB
    $ACET
    $NUVB
    $TIL
    $PALI
    $JSPR

    Recent Analyst Ratings for Graphite Bio Inc.

    DatePrice TargetRatingAnalyst
    2/23/2023$3.00 → $2.00Neutral → Underperform
    BofA Securities
    2/23/2023$3.00Overweight → Neutral
    Cantor Fitzgerald
    2/23/2023Outperform → Market Perform
    Cowen
    1/25/2023Buy → Neutral
    BTIG Research
    1/18/2023$7.00 → $3.00Buy → Neutral
    BofA Securities
    1/6/2023$11.00 → $2.00Outperform → Mkt Perform
    SVB Leerink
    1/6/2023$14.00 → $7.00Outperform → Market Perform
    BMO Capital Markets
    9/15/2022$12.00Overweight
    Cantor Fitzgerald
    6/17/2022$12.00Outperform
    BMO Capital Markets
    4/14/2022$18.00Buy
    BTIG Research
    See more ratings

    Graphite Bio Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Graphite Bio Appoints Alethia Young as Chief Financial Officer

      Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointment of Alethia Young as chief financial officer. Ms. Young joins Graphite Bio from Cantor Fitzgerald, where she served as senior biotech analyst and head of research, managing the equity research department covering small-cap, mid-cap and large-cap biotechnology companies. In this newly created position, Ms. Young will oversee the company's finance, investor relations and corporate communications functions, and will play a key role in overall corporate strategy. "On behalf of the e

      3/2/22 8:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    Graphite Bio Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      5/14/24 5:29:43 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • New insider Alpha Wave Ventures Gp, Ltd claimed ownership of 3,612,211 shares (SEC Form 3)

      3 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/28/24 4:31:03 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ra Capital Management, L.P. was granted 3,245,785 shares, bought $14,023,561 worth of shares (933,038 units at $15.03) and bought $976,514 worth of Common Stockj (64,971 units at $15.03) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:48:33 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Ra Capital Management, L.P.

      3 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:44:12 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Thunen Shelley B

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:44:10 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mccollum James W was granted 589,267 shares (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:42:24 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Guerard Frederic

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:40:57 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Scheiner Zachary

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:40:09 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Drapkin Kimberlee C

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:39:32 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Scheiner Zachary

      3 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:38:44 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    Graphite Bio Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Graphite Bio downgraded by BofA Securities with a new price target

      BofA Securities downgraded Graphite Bio from Neutral to Underperform and set a new price target of $2.00 from $3.00 previously

      2/23/23 8:58:13 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Graphite Bio from Overweight to Neutral and set a new price target of $3.00

      2/23/23 8:56:04 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio downgraded by Cowen

      Cowen downgraded Graphite Bio from Outperform to Market Perform

      2/23/23 6:14:16 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio downgraded by BTIG Research

      BTIG Research downgraded Graphite Bio from Buy to Neutral

      1/25/23 7:41:15 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio downgraded by BofA Securities with a new price target

      BofA Securities downgraded Graphite Bio from Buy to Neutral and set a new price target of $3.00 from $7.00 previously

      1/18/23 7:17:59 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Graphite Bio from Outperform to Mkt Perform and set a new price target of $2.00 from $11.00 previously

      1/6/23 8:11:38 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Graphite Bio from Outperform to Market Perform and set a new price target of $7.00 from $14.00 previously

      1/6/23 8:11:38 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Cantor Fitzgerald initiated coverage on Graphite Bio with a new price target

      Cantor Fitzgerald initiated coverage of Graphite Bio with a rating of Overweight and set a new price target of $12.00

      9/15/22 9:06:58 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • BMO Capital Markets initiated coverage on Graphite Bio with a new price target

      BMO Capital Markets initiated coverage of Graphite Bio with a rating of Outperform and set a new price target of $12.00

      6/17/22 7:29:43 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • BTIG Research initiated coverage on Graphite Bio with a new price target

      BTIG Research initiated coverage of Graphite Bio with a rating of Buy and set a new price target of $18.00

      4/14/22 7:28:48 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    Graphite Bio Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      5/14/24 5:29:43 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Ra Capital Management, L.P. was granted 3,245,785 shares, bought $14,023,561 worth of shares (933,038 units at $15.03) and bought $976,514 worth of Common Stockj (64,971 units at $15.03) (SEC Form 4)

      4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)

      3/25/24 8:48:33 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    Graphite Bio Inc. Financials

    Live finance-specific insights

    See more

    Graphite Bio Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

      Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte

      3/8/24 5:00:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • LENZ Therapeutics and Graphite Bio Announce Merger Agreement

      - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran

      11/15/23 7:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Healthpeak Properties Reports Third Quarter 2023 Results and Declares Quarterly Cash Dividend on Common Stock

      Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio

      10/30/23 7:00:00 AM ET
      $GRPH
      $PEAK
      Medicinal Chemicals and Botanical Products
      Health Care
      Real Estate Investment Trusts
      Real Estate
    • SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)

      SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

      4/8/24 2:46:09 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Graphite Bio Inc.

      SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

      3/28/24 4:30:24 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Graphite Bio Inc.

      SC 13D - LENZ Therapeutics, Inc. (0001815776) (Subject)

      3/28/24 4:16:06 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)

      SC 13G/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

      3/25/24 8:42:49 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Graphite Bio Inc. (Amendment)

      SC 13D/A - LENZ Therapeutics, Inc. (0001815776) (Subject)

      3/25/24 4:43:49 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Graphite Bio Inc.

      SC 13G - LENZ Therapeutics, Inc. (0001815776) (Subject)

      3/25/24 4:33:33 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Graphite Bio Inc.

      SC 13G - Graphite Bio, Inc. (0001815776) (Subject)

      2/5/24 4:48:54 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)

      SC 13G/A - Graphite Bio, Inc. (0001815776) (Subject)

      2/5/24 4:31:56 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D/A filed by Graphite Bio Inc. (Amendment)

      SC 13D/A - Graphite Bio, Inc. (0001815776) (Subject)

      11/17/23 4:38:26 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)

      SC 13G/A - Graphite Bio, Inc. (0001815776) (Subject)

      2/14/23 5:07:14 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    Graphite Bio Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics

      Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Graphite Bio, Inc. (NASDAQ:GRPH) ("Graphite" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Lenz Therapeutics, Inc. ("LENZ") pursuant to the Agreement and Plan of Merger, dated November 14, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.03 per share of Graphite's common stock, will be payable in cash to the stockholders of record as of March 18, 2024. The exact amount of the special dividend will be calculated afte

      3/8/24 5:00:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • LENZ Therapeutics and Graphite Bio Announce Merger Agreement

      - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics' lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Companies to host joint webcast today, November 15, 2023 at 8:00 a.m. ET LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ:GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock tran

      11/15/23 7:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Healthpeak Properties Reports Third Quarter 2023 Results and Declares Quarterly Cash Dividend on Common Stock

      Healthpeak Properties, Inc. (NYSE:PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the third quarter ended September 30, 2023. THIRD QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.12 per share, Nareit FFO of $0.46 per share, FFO as Adjusted of $0.45 per share, AFFO of $0.40 per share, and blended Total Same-Store Portfolio Cash (Adjusted) NOI growth of 6.0% – Third quarter new and renewal lease executions totaled 2.3 million square feet: • Outpatient Medical new and renewal lease executions totaled 2.1 million square feet, an all-time quarterly high, including a 1.3 millio

      10/30/23 7:00:00 AM ET
      $GRPH
      $PEAK
      Medicinal Chemicals and Botanical Products
      Health Care
      Real Estate Investment Trusts
      Real Estate
    • Graphite Bio Announces Departure of Chief Financial Officer

      Graphite Bio, Inc. (NASDAQ:GRPH) today announced that Alethia Young, the Company's Chief Financial Officer, will step down from her position to pursue other opportunities. Ms. Young will remain with the Company through June 30, 2023 to oversee her current responsibilities and ensure an orderly transition. "On behalf of the Board and the team at Graphite Bio, I would like to thank Alethia for her dedication and support. She has been an integral part of helping to lead the company since joining us last year. We wish her all the best in her next endeavors," said Josh Lehrer, M.D., M. Phil., Chief Executive Officer of Graphite Bio. "It has been an honor to serve as the first CFO of Graphite B

      6/23/23 7:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results

      Graphite Bio, Inc. (NASDAQ:GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results. "As announced last month, Graphite Bio has initiated a process to evaluate strategic alternatives that may result in changes to our business strategy," said CEO Josh Lehrer, M.D., M.Phil. "We are working expeditiously to complete this strategic review and look forward to providing an update in the future when appropriate." Recent Business Updates In February 2023, Graphite Bio announced its decision to discontinue development of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease and initiate a process to explore strategic alternatives. As a resu

      3/20/23 4:05:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring

      Graphite Bio, Inc. (NASDAQ:GRPH) today announced that it has completed a review of its business, including the status of its programs, resources and capabilities. The company has decided to discontinue further development of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease and to initiate a process to explore a range of strategic alternatives. "We believe that gene correction is the optimal way to treat sickle cell and many other genetic diseases. However, after an extensive assessment of the nula-cel program, we made the difficult decision to discontinue nula-cel development based on the time and resources needed to resume the CEDAR study and the evolving treatment landscape

      2/22/23 4:05:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease

      Graphite Bio, Inc. (NASDAQ:GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious adverse event in the first patient dosed with nula-cel, and the company's conclusion that the event is likely related to study treatment. As a result, the company will not meet its guidance for initial proof-of-concept data in mid-2023. The decision by Graphite Bio to voluntarily pause the CEDAR study follows a serious and unexpected adverse event of prolonged low blood cell counts (pancytopenia) requiring ongoing transfusion and growth factor support in the first patient dosed with nula-cel. The event

      1/5/23 4:05:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting

      Single-cell RNA sequencing of reticulocytes will be used to measure gene correction outcomes in sickle cell patients treated with nulabeglogene autogedtemcel (nula-cel) Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today presented preclinical results supporting the use of a single-cell RNA sequencing method to assess gene correction outcomes in patients treated with nulabeglogene autogedtemcel (nula-cel), an investigational gene-edited therapy for sickle cell disease (SCD). The findings are being presented in a p

      12/11/22 10:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference

      Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Thursday, Dec. 1, 2022, at 11:45 a.m. ET. The fireside chat will be webcast live from Graphite Bio's website at www.graphitebio.com in the Investors section. A replay of the webcast will be archived and available following the event. About Graphite Bio Graphite Bio is a clinical-stage, next-generation gene editing company dr

      11/21/22 8:00:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results

      Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023 Two abstracts accepted for 64th ASH Annual Meeting and Exposition in December Entered strategic partnership with Philadelphia-based WuXi Advanced Therapies for the manufacturing of nula-cel Bolstered company leadership with hiring of senior vice president of development $305.1 million in cash, cash equivalents and investments in marketable securities as of September 30, 2022; cash runway into fourth quarter 2024 Graphite Bio, Inc. (NASDAQ:GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with th

      11/9/22 4:05:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care

    Graphite Bio Inc. SEC Filings

    See more
    • SEC Form 424B3 filed by Graphite Bio Inc.

      424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/9/24 4:18:06 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Graphite Bio Inc.

      10-Q - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/8/24 5:11:18 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

      5/8/24 4:05:56 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Graphite Bio Inc.

      EFFECT - LENZ Therapeutics, Inc. (0001815776) (Filer)

      4/11/24 12:15:19 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 424B3 filed by Graphite Bio Inc.

      424B3 - LENZ Therapeutics, Inc. (0001815776) (Filer)

      4/10/24 7:37:49 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

      4/3/24 7:32:00 AM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-1 filed by Graphite Bio Inc.

      S-1 - LENZ Therapeutics, Inc. (0001815776) (Filer)

      3/29/24 4:46:24 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • Graphite Bio Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD Disclosure

      8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)

      3/21/24 8:22:01 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 8-K filed by Graphite Bio Inc.

      8-K - Graphite Bio, Inc. (0001815776) (Filer)

      3/19/24 4:31:05 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 8-K filed by Graphite Bio Inc.

      8-K - Graphite Bio, Inc. (0001815776) (Filer)

      3/14/24 4:37:00 PM ET
      $GRPH
      Medicinal Chemicals and Botanical Products
      Health Care